Loading...

MLTX MOONLAKE IMMUNOTHERAPEUTICS Product Launches 8-K Filing

MNLK

MLTX

MOONLAKE IMMUNOTHERAPEUTICS

(MLTX)

2025 8-K

Supply Agreement Signed

Quarterly Update

Loan Agreement Update

FDA Feedback Update

Financial Results

Trial Results Update

Financial Statements

Financial Statements

Investor Meetings

Financial Results

Financial Results

Investor Presentation

Financial Results Announcement

FDA and EMA Positive Feedba...

Annual General Meeting

Earnings Report

Financial Results Announcement

Regulatory Approval

Financial Results Announcement

Phase 2 Trial Results

Filing with Quantitative Data

Compensation Increases

Financial Results Announcement

Underwriting Agreement and ...

Annual General Meeting

Quantitative Data

Quantitative Data

Financial Results Announcement

External Links:

On September 28, 2025, MoonLake Immunotherapeutics announced the week 16 results from its Phase 3 VELA-1 and VELA-2 trials for treating moderate-to-severe hidradenitis suppurativa. A webcast to discuss the results was held on September 29, 2025.

AI Assistant

MOONLAKE IMMUNOTHERAPEUTICS

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.